「de」の検索結果
173件：16～20件目を表示
-
f Central Retinal Artery Occlusion Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces that it has started Phase III clinic...
https://www.senju.co.jp/system/files/content_news/2024-05/ENG_20240509.pdf -
AVIS” in Japan. MIEr for NAVIS can sharpen images on NAVIS-AZU or NAVIS-CL* by installing Logic and Design’s image sharpening algorithm. We aim to promote “more visibility” by providing products and s...
https://www.senju.co.jp/system/files/content_news/2024-04/ENG_20240423_0.pdf -
ting Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
ting Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
n of Software for Dry-eye Analysis Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of softwa...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906_0.pdf